Anadys Forms Collaboration With Gilead to Discover Novel Antiviral Compounds; Anadys' uHTS-ATLAS to be Used to Screen Important and Challenging Viral Target

SAN DIEGO, Jun 10, 2002 (BW HealthWire) -- Anadys Pharmaceuticals, Inc. ("Anadys") and Gilead Sciences, Inc. (Nasdaq: GILD) announced today that they have entered into a collaboration to discover novel antiviral compounds. As part of the collaboration agreement, Anadys will design, configure and run uHTS-ATLAS(TM) screens against a key viral target selected by Gilead. This agreement leverages Anadys' powerful ability to screen for small molecules that bind to proteins that are difficult to screen using conventional methods.

Under the terms of the agreement, Anadys will design and run uHTS-ATLAS(TM) assays against Gilead's compound collection. uHTS-ATLAS(TM) is Anadys' proprietary, fully-automated, affinity-based screening technology capable of screening 100,000 compounds in one day. The technology is capable of delivering this throughput using discrete compounds, mixtures or natural products against protein targets of either known or unknown function. Gilead will have exclusive rights to develop and commercialize any products resulting from compounds discovered in the collaboration.

"We are very pleased to collaborate with Gilead on this important and challenging viral target," said Dr. Steve Worland, Chief Scientific Officer of Anadys. "Gilead is viewed as one of the premier organizations involved in antiviral research, and their decision to employ uHTS-ATLAS(TM) is important validation for our technology. It also highlights one of the key advantages of our technology in that we can screen targets that have traditionally been a challenge."

"Gilead is committed to using state-of-the-art technologies to find novel medicines to combat viral infections," said Dr. William Lee, Senior Vice President, Research, Gilead Sciences. "After reviewing a number of screening technologies, we chose to apply uHTS-ATLAS(TM) to help us further advance this important program."

"The collaboration with Gilead further illustrates Anadys' overall commitment to broadening our efforts in the antiviral therapeutic area," said Michael Kamdar, Vice President of Corporate Development and Strategy for Anadys. "We look forward to building a long term relationship with Gilead, which has a strong record of developing and commercializing antiviral therapies."

Specific financial terms were not disclosed but they include an upfront payment, research success payments, R&D support, and potential for product milestone payments and royalties.

    About Anadys Pharmaceuticals
Anadys Pharmaceuticals, Inc. ("Anadys" or the "Company") is a new generation drug discovery company committed to applying an integrated approach that combines biology and chemistry to develop new small molecule therapeutics. The Company is committed to developing novel powerful antibiotics and medicines to treat viral infections. To that end, Anadys has assembled and integrated a proprietary suite of technologies to identify novel targets (using GATE(TM) and Riboproteomics(TM)), screen them for small molecule effectors (uHTS-ATLAS(TM) and SCAN(TM)), and develop clinical candidates using its considerable capabilities in high-output medicinal chemistry. Anadys has a specific capability to exploit RNA-related targets and novel chemistries to find new medicines using its leadership position in Riboproteomics(TM). RNA-related targets have been validated with the approval of drugs such as neomycin, Zyvox(R), and Zithromax(R). Anadys intends to harness this integrated suite of technologies to propel a strong and continual pipeline of drug candidates into the clinic.

    For more information, please visit
    About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases worldwide. The company has five marketed products and focuses its research and clinical programs on anti-infectives, including antivirals, antifungals and antibacterials. Headquartered in Foster City, CA, Gilead has operations in the United States, Europe and Australia.

    For more information, please visit
CONTACT:          Anadys Pharmaceuticals, Inc.
                  David M.K. Nelson, Ph.D., Associate Director, Corporate
                  Development & Investor Relations
                  Gilead Sciences
                  Susan Hubbard, Investor Relations, 650/522-5715        

Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
Copyright (C) 2002 Business Wire.  All rights reserved.